Latest Health News
Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season
Los Angeles, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Important Information for Readers:…
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences…
Major shareholder announcement
Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC…
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025 16:15 ET | Source: Zenas BioPharma WALTHAM, Mass., Dec.…
Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes
ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology…
Is SkinnyRx the Best GLP-1 Vendor for 2026? Platform Offers Compounded Semaglutide in Three Forms Starting at $199/Month as New Year Weight Loss Season Approaches
Sacramento, Dec. 18, 2025 (GLOBE NEWSWIRE) -- With the New Year fast…
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
December 18, 2025 19:00 ET | Source: Mesa Laboratories, Inc. LAKEWOOD, Colo.,…
Sequana Medical Announces Granting of Key Additional U.S. Patent for DSR
Ghent, Belgium, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Builds upon existing granted…
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
December 17, 2025 20:48 ET | Source: InnoCare Pharma BEIJING, Dec. 17,…
